GlossaryMass Tort & MDL ProcedureInnovator Liability

Innovator Liability

Innovator liability is a theory of tort liability under which a brand-name pharmaceutical manufacturer may be held liable for injuries caused by a generic version of its drug, on the theory that the brand manufacturer authored the warning label that both the brand and generic products are required to use, and that its negligent failure to update or adequately warn extends to patients who took the generic equivalent. The theory emerged from the tension created by PLIVA, Inc. v. Mensing (2011), in which the Supreme Court held that generic manufacturers cannot be sued for failure-to-warn claims because federal law requires generic labeling to match the brand-name label exactly, leaving generic-drug patients with no viable failure-to-warn remedy against the entity that actually manufactured the product they took. Innovator liability, first recognized by the California Court of Appeal in Conte v. Wyeth (2008), attempts to close this gap by allowing the injured generic-drug patient to sue the brand manufacturer instead. The overwhelming majority of state courts to consider the theory have rejected it, reasoning that liability should not extend to a defendant that never manufactured, sold, or profited from the product the plaintiff actually used, making it a minority and jurisdiction-specific theory rather than a generally available cause of action.

Why It Matters in Underwriting

Because innovator liability is recognized in only a small number of jurisdictions, its viability is a threshold, state-specific screening question for any docket involving generic-drug plaintiffs seeking to reach a brand manufacturer, and funders must confirm the applicable state's position before valuing such claims at all.

A claim inventory built on the assumption that innovator liability will be available is a materially higher-risk investment than one where plaintiffs can proceed against the actual manufacturer, and funders should treat innovator-liability-dependent claims in unsettled or adverse jurisdictions as speculative until a controlling appellate ruling establishes the theory locally.

Mass Tort & MDL Procedure

The procedural and settlement-administration machinery of multi-district litigation — case management orders, causation gatekeeping, settlement trusts, and the mechanics that determine when and how a mass tort docket resolves.

Mass Tort Finance
Discuss a matter involving innovator liability.
Confidential review from our institutional underwriting team.